专利检索 ap:("Ela Pharma Ltd") AND inv:"Boris Khalfin" 第 1 页

1.

发明授权
Substituted imidazoles for preventing and/or treating cell or tissue necrosis 有权

公开(公告)号：US11945787B2

公开(公告)日：2024-04-02

申请号：US17201201

申请日：2021-03-15

申请人： Ela Pharma Ltd

发明人： Ilana Nathan , Boris Khalfin

IPC分类号： C07D233/04 , A61K31/00 , A61K31/167 , A61K31/4045 , A61K31/415 , A61K31/4178 , A61K31/4196 , A61K31/426 , A61K31/428 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/536 , A61K45/06 , A61P25/00 , C07C233/24 , C07D233/44 , C07D233/48 , C07D265/22 , C07D275/06 , C07D277/42 , C07D277/56 , C07D405/06 , C07D417/12 , C12N5/077 , C12N15/113

CPC分类号： C07D265/22 , A61K31/00 , A61K31/167 , A61K31/4045 , A61K31/415 , A61K31/4178 , A61K31/4196 , A61K31/426 , A61K31/428 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/536 , A61K45/06 , A61P25/00 , C07C233/24 , C07D233/44 , C07D233/48 , C07D275/06 , C07D277/42 , C07D277/56 , C07D405/06 , C07D417/12 , C12N5/0669 , C12N15/1137 , C12Y304/14001 , C12Y304/21036 , C12N2310/14 , C12N2501/30 , C12N2501/999

摘要： Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising the same, and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis are described. The compounds include imidazoles of Formula VI:

wherein G1 is pyrrolidine, pyrazolidine, imidazolidine piperidine, or piperazine and G2 is alkyl, cycloalkyl, heterocycle, or aryl. The pyrrolidine, pyrazolidine, imidazolidine, piperidine, or piperazine of G1 and the alkyl, cycloalkyl, heterocycle, or aryl of G2 are optionally substituted with one or more substituents independently selected from the group consisting of halogen, NO2, CN, C1-C6 alkyl, C1-C6 haloalkyl, NH2, OH, OC1-C6 alkyl, C(O)H, C(O)C1-C6 alkyl, C(O)NH2, C(O)OH, and C(O)OC1-C6 alkyl. Variations applications for the described compounds, and combination therapies are further described as well.

2.

发明申请
COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO 有权

公开(公告)号：US20210309620A1

公开(公告)日：2021-10-07

申请号：US17201201

申请日：2021-03-15

申请人： Ela Pharma Ltd

发明人： Ilana Nathan , Boris Khalfin

IPC分类号： C07D265/22 , A61K31/4178 , A61K31/426 , A61K31/454 , C07D277/42 , C12N15/113 , A61K31/00 , A61K31/496 , A61K31/415 , C07D405/06 , C07D277/56 , A61K31/4439 , C07D233/44 , C07D417/12 , A61K31/4196 , A61K31/4045 , A61P25/00 , A61K31/167 , A61K31/428 , A61K31/536 , A61K45/06 , C07C233/24 , C07D233/48 , C07D275/06 , C12N5/077

摘要： Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.

3.

发明授权
Substituted thiazoles for preventing and/or treating cell or tissue necrosis 有权

公开(公告)号：US10968185B2

公开(公告)日：2021-04-06

申请号：US15564836

申请日：2016-04-07

申请人： ELA PHARMA LTD

发明人： Ilana Nathan , Boris Khalfin

IPC分类号： A61K31/427 , C07D277/20 , C07D265/22 , A61K31/4178 , A61K31/426 , A61K31/454 , C07D277/42 , C12N15/113 , A61K31/00 , A61K31/496 , A61K31/415 , C07D405/06 , C07D277/56 , A61K31/4439 , C07D233/44 , C07D417/12 , A61K31/4196 , A61K31/4045 , A61P25/00 , A61K31/167 , A61K31/428 , A61K31/536 , A61K45/06 , C07C233/24 , C07D233/48 , C07D275/06 , C12N5/077

摘要： Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis are described. The compounds include thiazoles of Formula II, where G1 is an optionally substituted pyrrolidine, an optionally substituted pyridine, an optionally substituted aryl, an optionally substituted piperidine, an optionally substituted piperazine, an optionally substituted imidazolidine, or an optionally substituted pyrazolidine. G3 is or G3 is an optionally substituted alkyl, an optionally substituted aryl or an optionally cyloalkyl. G2 is an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted cyloalkyl or an optionally substituted heterocycle. Various applications for the described compounds, and combination therapies are described as well.